View in EDS HTML Full Text PDF Full Text

Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression.

Saved in:
Bibliographic Details
Title: Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression.
Authors: Blomquist, Mylan R.1,2,3,4 (AUTHOR), Noviello, Teresa M. R.5,6 (AUTHOR), Sereduk, Christopher1,2 (AUTHOR), Grief, Dustin1,2,4 (AUTHOR), Caruso, Francesca P.7 (AUTHOR), Sharma, Ritin8,9 (AUTHOR), Garcia-Mansfield, Krystine8 (AUTHOR), Pirrotte, Patrick8,9 (AUTHOR), Kloss, Jean1 (AUTHOR), D'Angelo, Fulvio10 (AUTHOR), Marin, Bianca M.11 (AUTHOR), Porath, Kendra11 (AUTHOR), Jain, Sonia11 (AUTHOR), Rabichow, Benjamin4 (AUTHOR), Ensign, Shannon P. Fortin1,12 (AUTHOR), Iavarone, Antonio6,10 (AUTHOR), Paladino, Antonella13 (AUTHOR), Sarkaria, Jann N.11 (AUTHOR), Loftus, Joseph C.1 (AUTHOR), Ceccarelli, Michele5,6 (AUTHOR) mxc2982@miami.edu
Source: Journal of Translational Medicine. 10/21/2025, Vol. 23 Issue 1, p1-16. 16p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14795876
DOI:10.1186/s12967-025-07216-5